Viking Therapeutics, Inc. (vktx)
VKTX — Company Overview
Investors tracking VKTX follow a Biotechnology name listed on NCM within Healthcare.
| Ticker | VKTX |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NCM |
| Market cap | $4.86B |
| Last price | $41.65 |
| Size category | Mid Cap |
VKTX — Business Description
The business profile of Viking Therapeutics, Inc. (VKTX) reflects its role in Biotechnology. Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and…
Official website: https://www.vikingtherapeutics.com.
VKTX — Investment Thesis
Viking Therapeutics, Inc. (VKTX) attracts investors weighing Biotechnology fundamentals against current market pricing.
- Equity market capitalization is approximately $4.86B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
VKTX — Financial Health
VKTX financial profile reflects operating efficiency and capital structure using available market fundamentals.
Profit margin near 0.0% leaves a narrower cushion versus higher-margin peers. Negative free cash flow of $-230.79M may require careful capital allocation.
| Forward P/E | -9.46× |
| Price / Book | 11.90× |
| Gross margin | 0.0% |
| Operating margin | 0.0% |
| Profit margin | 0.0% |
| Return on equity | -88.9% |
| Debt / Equity | 1.00 |
| Free cash flow | $-230.79M |
VKTX — Growth Outlook
Growth outlook for Viking Therapeutics, Inc. (VKTX) depends on demand trends in Biotechnology and the company's ability to convert revenue into sustainable earnings.
- Price is 3.5% below the 52-week high.
VKTX — Competitive Position
Viking Therapeutics, Inc. (VKTX) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Biotechnology.
- Market capitalization of $4.86B places VKTX among mid-cap peers.
- Gross margin of 0.0% should be benchmarked against direct competitors.
VKTX — Strengths
Strengths for Viking Therapeutics, Inc. (VKTX) inferred from public financial metrics:
- Moderate leverage (debt/equity 1.00).
- Price near 52-week highs — positive price momentum on public markets.
VKTX — Weaknesses
Weaknesses and pressure points for Viking Therapeutics, Inc. (VKTX) based on available data:
- Thin profit margin (0.0%).
- Negative free cash flow ($-230.79M).
VKTX — Opportunities
- Opportunities depend on industry trends and execution — monitor quarterly filings and guidance.
VKTX — Risks
- Thin margins leave less room for operational missteps.
VKTX — Summary
Viking Therapeutics, Inc. (VKTX) is a mid-cap Healthcare company focused on Biotechnology, listed on NCM. Last price $41.65 with market cap $4.86B. Notable strengths include moderate leverage (debt/equity 1.00). Key watch items include thin profit margin (0.0%). Review free estimates and earnings pages for VKTX; upgrade for institutional ownership and live headlines.
Start Free — open VKTX in Vest Terminal
Access live data, filings, ownership, and analysis for Viking Therapeutics, Inc..
Viking Therapeutics, Inc. FAQ
What does Viking Therapeutics, Inc. (VKTX) do?
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone…
What is VKTX's P/E ratio?
Viking Therapeutics, Inc. has a trailing P/E of N/A× based on publicly available market data.
Does VKTX pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is VKTX in?
Viking Therapeutics, Inc. is classified in Healthcare (Biotechnology) on NCM.
What is VKTX's market capitalization?
Approximate market cap: $4.86B.
What are the main risks for VKTX?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of VKTX?
Potential positives include moderate leverage (debt/equity 1.00), price near 52-week highs — positive price momentum on public markets.
Where can I get analyst estimates for VKTX?
Public analyst price targets and consensus for Viking Therapeutics, Inc. are on the free /stocks/vktx/estimates page. Deeper estimate history and models are available in Vest Terminal.